Albany, NY -- (SBWIRE) -- 05/04/2017 -- Head & neck cancer is characterized as a group of cancers, which initiate in squamous cells that line the mucosal surface of head and neck. It is also called squamous cell carcinoma. In the head & neck cancer, different types of malignant tumors develop in and around the larynx, throat, nose, mouth, and sinus. If the cancer is found only in the squamous layer of cells, it is known as carcinoma in situ (CIS). If the cancer grows beyond the squamous cell layer and moves deeper, it is called invasive squamous cell carcinoma. Nose, throat, and ears are the most common body parts affected by the head & neck cancer. The common symptoms include headache, common cold, change in voice, soreness in the mouth, and swelling of jaws. More than 70% of head & neck cancers are caused by alcohol and tobacco consumption. Other factors include exposure to radiations, infection by human papilloma virus (HPV) Type 16, and consumption of preserved and salted food.
Get Sample Copy of this Report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22919
Introduction of advanced chemotherapy and other treatment options and increase in per capita income of people are major factors driving the head & neck cancer market. However, high cost of targeted therapies and low awareness in developing economies about technologically advanced and novel therapies are factors expected to hamper the market for head & neck cancer during the forecast period.
The global head & neck cancer market can be segmented on the basis of type of cancer, diagnostic technique, type of treatment, and end-user.
Based on cancer type, the market has been segmented into salivary gland cancer, oropharyngeal (oral cavity) cancer, nasopharyngeal cancer, laryngeal cancer, and others. The oropharyngeal cancer segment accounted for the maximum market share in 2016. This can be attributed to the increasing consumption of tobacco and alcohol and chewing of betel nuts. Rising incidence of exposure to radiations and increasing intake of processed and raw meat as well as preserved food are the major factors anticipated to boost the oropharyngeal cancer segment of the head & neck cancer market by 2025.
Based on diagnostic technique, the global head & neck cancer market has been divided into biopsy, blood tests, diagnostic imaging equipment, endoscopy screening, and dental diagnostic equipment. The diagnostic imaging equipment segment has been further divided into PET/CT scan, MRI, and X-ray. The endoscopy screening segment has been sub-divided into pharyngoscopy, laryngoscopy, and others. In terms of revenue, the diagnostic imaging equipment segment held the maximum market share in 2016. This is due to the rising incidence of oropharyngeal cancer. X-ray and MRI segments are expected to continue to lead the market during the forecast period, owing to the rising demand for cost-effective and non-invasive diagnostic techniques.
Based on treatment type, the global head & neck cancer market has been segmented into surgery, chemotherapy, radiation therapy, targeted therapy, and others. The radiation therapy segment has been further classified into internal therapy and external therapy. Radiation therapy is the most preferred type of therapy. The segment accounted for the maximum share in the global head & neck cancer market in 2016. The radiation therapy segment and the surgery segment are expected to dominate the head & neck cancer market during the forecast period, due to the rising prevalence of head and neck cancer. On the other hand, the targeted therapy segment is expected to expand at the maximum CAGR during the forecast period, due to the increasing investment in research and development of targeted therapy by key players in the market and the rising demand for an effective and safe therapy with less side-effects.
Based on end-user, the global head & neck cancer market can be segmented into hospitals, ambulatory surgical centers, and clinics. The hospitals segment held the leading share in the global head & neck cancer market in 2016, owing to favorable reimbursement policies and the availability of well-qualified and specialized staff in hospitals. Government funding to improve the health care infrastructure in emerging economies and long-term procedures of chemotherapy and other surgeries are factors likely to propel the hospitals segment of the market for head & neck cancer by 2025.
Geographically, the global head & neck cancer market can be divided into five regions viz. North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a major share of the global market in 2016, which is attributable to technological advancements in the medical sector in the region. However, the market in Asia Pacific is expected to expand at the maximum CAGR from 2017 to 2025, owing to the improving health care facilities in China and Japan and rising awareness among the people about diseases such as cancer. In terms of revenue, North America is estimated to remain dominant in the global head & neck cancer market during the forecast period. The rising investment by key players in R&D activities for cancer treatment with a technologically compatible and superior therapeutic approach is a major factor expected to boost the head & neck cancer market in North America during the forecast period.
View Report @ http://www.transparencymarketresearch.com/head-neck-cancer-market.html
Prominent players in the global head & neck cancer market are DentalEZ, Inc., Koninklijke Philips N.V., Siemens Healthcare Private Limited, AdDent Incorporated, GE Healthcare, AB SCIENCES, Bayer AG, Boston Biomedical, and Bristol-Myers Squibb Company. Prominent players in the market in developed countries are focusing on the targeted therapy segment of the head & neck cancer market.